CSL Seqirus revenue is projected to benefit from the supply of H5 avian flu vaccines in the second half, with FLUAD launch preparations underway in Germany. CSL Vifor is set to maintain its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback